Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 325 results for "mirati"

Stocks Hitting 52-Week Lows

Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares touched a new 52-week low of $6.54. Mirati Therapeutics shares have dropped 78.59 percent over the past 52 weeks, while the S&P 500 index has declined 1.84 percent in the same period. Adamis ..., 1 month ago

15 images for mirati

ADVFN India, 1 month ago, 1 month ago, 1 month ago
Schaeffers Research, 1 month ago
Nasdaq, 1 month ago
Motley Fool, 1 month ago
BioSpace, 1 month ago
Yahoo! Singapore, 1 month ago
Yahoo! Singapore, 1 month ago
Oregon Public Broadcasting, 2 months ago

Mirati Therapeutics Inc. (MRTX) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research downgraded shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) from a hold rating to a sell rating in a research note released on Wednesday morning. According to Zacks, Mirati Therapeutics, Inc. is a biopharmaceutical company.
 Ticker Report2 weeks ago Mirati Therapeutics Inc. (MRTX) Rating Lowered to Sell at Zacks Investment Research  SleekMoney2 weeks ago Short Interest in Mirati Therapeutics, Inc. (MRTX) Grows By 28.5%  Ticker Report3 weeks ago Mirati Therapeutics Inc. (MRTX) Short Interest Update  WKRB News3 weeks ago

MIRATI THERAPEUTICS : Announces Change In Executive Leadership

By a News Reporter-Staff News Editor at Clinical Oncology Week -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that Mark Gergen will step down as Executive Vice President and Chief Operations Officer to pursue other opportunities, ...
 4 Traders3 weeks ago Mirati Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 8, 2016)  Equities.com1 month ago Mirati Therapeutics operations chief bids adieu  Seeking Alpha1 month ago San Diego's Mirati Therapeutics COO Resigns to Pursue Other Opportunities  BioSpace1 month ago

SC 13D/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] SEC Accession No. 0001193125-16-616805 Filing Date 2016-06-08 2016-06-08 17:15:33 Filing Date Changed 2016-06-08 Group Members AARON I. DAVISBOXER ASSET ...
 SEC Filings1 month ago Boxer Capital Just increased Mirati Therapeutics Inc's Stake  Octafinance1 month ago CT ORDER - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC2 months ago SC 13D/A - BAKER BROS. ADVISORS LP (0001263508) (Filed by)  SEC Filings1 month ago

Mirati Takes Home The Share Price Wooden Spoon

The tradition of wild biotech stock price movements on Asco Monday when investors get their first opportunity to react to clinical data emerging over the weekend was rather muted this year, reflecting the relative absence of high-impact late-stage ...
 Seeking Alpha1 month ago
Motley Fool

Why Sturm Ruger, Mirati Therapeutics, and Barracuda Networks Slumped Today

Monday brought a solid reversal to the downward movement stock market investors suffered late last week. Major market benchmarks rose between 0.5% and 0.75% as market participants chose to see the positives in comments from U.S. central bank chief ...
 Motley Fool1 month ago
Motley Fool

Why Mirati Therapeutics, Inc.'s Shares Are Being Obliterated Today

What: Investors in Mirati Therapeutics ( NASDAQ:MRTX ) are having a rough start to the week. The clinical-stage biotech's stock is down more than 40% as of 11:30 a.m. EDT after management shared a few clinical updates that caused some investors to ...
 Motley Fool1 month ago

Side effects excessive in early-stage study of Mirati's lead product candidate, new formulation being implemented in Phase 2; shares off 40%

Thinly traded micro cap Mirati Therapeutics ( MRTX -40.1%) plummets in early trading on a 6x surge in volume in response to its update on its clinical trials. The company reported results from a Phase 1b study evaluating lead product glesatinib , a ...
 Seeking Alpha1 month ago

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Upgrade Ratio At 0

Mirati Therapeutics, Inc. (NASDAQ:MRTX) strong sell score is 0 while buy rating count is 1. Moderate sell ratings are 0 while moderate buy calls are 2. Hold ratings count is 1. As many as 2 analysts initiated coverage on Mirati Therapeutics, Inc.
 Markets Daily1 week ago NASDAQ:MRTX Stockholder Notice: Investigation of Mirati Therapeutics, Inc.  Empowered News2 weeks ago Mirati Therapeutics Inc. (NASDAQ:MRTX) Given Consensus Recommendation of Buy by Analysts  American Banking News - Earnings2 weeks ago INVESTIGATION FOR INVESTORS IN SHARES OF MIRATI THERAPEUTICS, INC. (NASDAQ : MRTX) Announced  4 Traders1 month ago


. MIRATI THERAPEUTICS (NASDAQ:MRTX) Smart Scan Chart Analysis confirms that a short term counter trend move is underway. When this action is over look for the longer term negative trend to resume. Downtrend with money management stops. The ...
 INO.com2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less